How well does spirometry capture the symptom range in primary ciliary dyskinesia? – a cross-sectional national study
Abstract
Introduction
Patients with primary ciliary dyskinesia (PCD) present a variety of respiratory symptoms. Spirometry, particularly forced expiratory volume in 1 s (FEV1), is the most commonly used outcome measure in clinical follow-up, however, it is not known how well it captures the range of respiratory symptoms experienced by patients.
Methods
We sent the FOLLOW-PCD questionnaire to all patients ≥14 years and parents of children, registered in the Swiss PCD Registry, asking about upper and lower respiratory symptoms. In patients who had a routine lung function done within a year of survey completion, we extracted data from clinical records and calculated spirometric indices z-scores based on the Global Lung Function Initiative references. We used linear regression to study associations between FEV1, forced vital capacity (FVC), FEV1/FVC and frequency of respiratory symptoms, adjusted for age, sex, and regular physiotherapy.
Results
64 out of 99 invited patients (67%) completed the survey; for 54 of them (median age 24 years, IQR 15-47; 50% females) we also had an FEV1 measurement (mean z-score - 2.29 [- 3.37 – −1.03]), with 2.2 months median time between survey and lung function test. Patients reporting wheeze (76%) had lower FEV1 and FEV1/FVC z-scores (FEV1 z-score for infrequent and frequent wheeze compared to no wheeze: −1.13 [95%CI −2.13 – −0.12] and −1.11 [−2.20 – - 0.20] respectively). Similarly patients reporting frequent shortness of breath (29.5%) had also lower FEV1 and FEV1/FVC z-scores (FEV1 z-score for frequent shortness of breath compared to no shortness of breath: −1.27 [−2.50 – −0.04]). We found no signs of association between reported nasal symptoms, snoring, cough, sputum production, and chest pain with FEV1, FVC or FEV1/FVC.
Conclusion
In our study, self-reported wheeze and frequent shortness of breath were associated with lower FEV1 and FEV1/FVC, commonly used for patient follow-up. However, we need additional outcome measures e.g., lung clearance index, imaging outcomes, or upper airway assessments, together with regular and standardised assessment of patient-reported symptoms, to capture the range of respiratory morbidity patients with PCD experience in daily life and guide management successfully.
Related articles
Related articles are currently not available for this article.